J
Jan Styczyński
Researcher at Nicolaus Copernicus University in Toruń
Publications - 400
Citations - 7175
Jan Styczyński is an academic researcher from Nicolaus Copernicus University in Toruń. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 35, co-authored 357 publications receiving 5241 citations. Previous affiliations of Jan Styczyński include Boston Children's Hospital & VU University Amsterdam.
Papers
More filters
Journal ArticleDOI
Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia.
Jan Styczyński,P. Reusser,H. Einsele,R de la Cámara,Catherine Cordonnier,Katherine N. Ward,Per Ljungman,Dan Engelhard +7 more
TL;DR: These guidelines on the management of HSV, VZV and EBV infection in patients with hematological malignancies and after SCT were prepared by the European Conference on Infections in Leukemia following a predefined methodology.
Journal ArticleDOI
Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation
Andreas H. Groll,Elio Castagnola,Simone Cesaro,Jean Hugues Dalle,Dan Engelhard,William W. Hope,Emmanuel Roilides,Jan Styczyński,Adilia Warris,Thomas Lehrnbecher +9 more
TL;DR: A group that reviewed the scientific literature on IFDs and graded the available quality of evidence according to the Infectious Diseases Society of America grading system concluded that the current state of knowledge on IFD diagnosis, prevention, and management is inadequate.
Journal ArticleDOI
Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report
Jakob Passweg,Helen Baldomero,Peter Bader,Chiara Bonini,R. F. Duarte,Carlo Dufour,Andrew R. Gennery,Kröger N,Jürgen Kuball,Francesco Lanza,Silvia Montoto,Arnon Nagler,John A. Snowden,Jan Styczyński,Mohamad Mohty +14 more
TL;DR: Use of haploidentical donors for allogeneic HSCT continues to grow: 2012 in 2015, a 291% increase since 2005, and growth is seen for all diseases.
Journal ArticleDOI
Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT
Per Ljungman,R de la Cámara,C. Cordonnier,H. Einsele,D. Engelhard,P Reusser,Jan Styczyński,K. Ward +7 more
TL;DR: These recommendations were prepared by the European Conference on Infections in Leukaemia following a predefined methodology and the quality of evidence and level of recommendation were graded according to the Center for Disease Control (CDC) criteria.
Journal ArticleDOI
Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines
Jan Styczyński,W.J.F.M. van der Velden,Christopher P. Fox,Dan Engelhard,R de la Cámara,Catherine Cordonnier,Per Ljungman +6 more
TL;DR: Rituximab, reduction of immunosuppression and Epstein-Barr virus-specific cytotoxic T-cell therapy are recommended as first- line therapy, whilst unselected donor lymphocyte infusions or chemotherapy are options as second-line therapy; other methods including antiviral drugs are discouraged.